Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Prostate cancer update.

Brian I Rini¹, Eric J Small

¹University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA. brini@medicine.utsf.edu

Current Opinion in Oncology

|May 1, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026

Same author

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026

Same author

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026

Same author

Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The oncologist·2026

Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026

Same author

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Nature reviews. Clinical oncology·2026

Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026

Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026

Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026

Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026

Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026

Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026

See all related articles

This review covers prostate cancer advances from 2000-2001, focusing on biochemical relapse treatments, new androgen deprivation therapy methods, bisphosphonates, and immunotherapy for hormone-refractory disease.

Area of Science:

Oncology
Urology

Background:

Prostate cancer treatment is evolving.
Focus is shifting towards managing relapse and improving therapy efficacy.

Purpose of the Study:

To review significant advancements in prostate cancer research.
To cover developments between November 2000 and October 2001.

Main Methods:

Literature review of published studies.
Analysis of recent findings in prostate cancer therapy.

Main Results:

Exploration of novel androgen deprivation therapy (ADT) strategies.
Investigation into bisphosphonates and immunotherapy.
Continued research into androgen independence and hormone-refractory prostate cancer.

Related Experiment Videos

Conclusions:

Significant progress has been made in understanding and treating advanced prostate cancer.
New therapeutic avenues are emerging for patients with biochemical relapse and hormone-refractory disease.